Final Inflation Reduction Act Guidance Risks Stifling Innovation for Rare Disease Community
Today, the Centers for Medicare and Medicaid Services (CMS) finalized a key component of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program (MDPNP). Unfortunately, today’s guidance threatens vital innovation …
Read more